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Reported herein is a 25-year-old woman who was treated for a large and highly atypical prolactin-producing
pituitary adenoma. On presentation, she exhibited right hemiparesis and left-sided visual loss, associated with
amenorrhea. A massive (>5 cm) intra- and suprasellar lesion was seen on imaging, and her serum prolactin level
was 4408 ng/ml. The patient received dopamine agonist treatment preoperatively for 4 weeks. To resect the tumor,
a two-stage excision was required. Histologically, the specimen was composed of polygonal or spindle cells
showing marked nuclear pleomorphism and/or multinucleation. Fibrosis was also focally conspicuous. Differential
diagnoses included pituitary adenoma, pituitary carcinoma, pituicytoma, paraganglioma, spindle cell oncocytoma,
and meningioma. Immunohistochemically, the tumor cells were positive for prolactin, chromogranin-A, and
synaptophysin, but were negative for glial fibrillary acidic protein, S-100 protein, epithelial membrane antigen, and
vimentin. No apparent cerebrospinal or systemic metastases are found. Ultimately, prolactin-producing pituitary adenoma
was diagnosed. Our case highlights the difficulty in definitively diagnosing an unusual prolactin-producing adenoma
based on histopathology alone and the importance of referring to clinical information and immunohistochemical
findings when deriving the diagnosis.
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In tissue sections, prolactin (PRL)-producing pituitary
adenomas typically present as monotonous arrays of
chromophobic cells in diffuse, papillary, or sinusoidal
proliferations. Such cells generally are of uniform size,
lacking both nuclear atypia and mitotic figures. Cystic
change, bleeding, or calcification may be observed in the
event of pituitary apoplexy. Likewise, dopamine agonist
therapy may alter tumor histology, resulting in negative
immunoreactivity for PRL; cellular shrinkage, degener-
ation, or necrosis; acellular or fibrotic areas; and other
effects [1–3].
In this report, an unusual occurrence of prolactinoma is
detailed. As opposed to the ordinarily bland picture of such
lesions, the alarming degree of atypia we observed raised
suspicions of pituitary carcinoma, paraganglioma, and
pituicytoma. The histologic attributes of this particular* Correspondence: mikikoss@fukuoka-u.ac.jp
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prior publications.Case presentation
A 25-year-old female patient had noticed left-sided
visual loss and amenorrhea 2 years prior to being seen,
with right hemiparesis developing 6 months beforehand.
Aggravated symptoms (drooping at corner of right lip
and bilateral temporal hemianopia) finally prompted
hospitalization. At that time, a massive (>5 cm) tumor of
intra- and suprasellar location, excluding mesencephalon
backward, was seen on computerized tomography (CT)
of the head (Fig. 1a). Further testing revealed an exceed-
ingly high-serum level of prolactin (PRL) (4408 ng/ml),
whereas levels of all other pituitary hormones were within
reference ranges (growth hormone (GH), 0.50 ng/ml;
luteinizing hormone (LH), 2.60 mIU/ml; follicle-
stimulating hormone (FSH), 4.57 mIU/ml; adrenocortico-
tropic hormone (ACTH), 37.4 pg/ml; thyroid-stimulating
hormone (TSH), 2.68 μIU/ml). T1-weighted magnetic res-
onance (MR) imaging with contrast (gadolinium) showed
homogeneous tumor enhancement, but adjacent tissueicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Pretreatment (a) and preoperative (b) coronal T1-weighted magnetic resonance images with contrast (gadolinium). Prior to surgery, slight
dilatation of right lateral ventricle evident (b), compared with baseline status (before cabergoline therapy) (a)
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not regress, despite a 4-week course of the dopamine
analog, cabergoline (1 mg/week), and serum PRL level
(2207 ng/ml) remained elevated. Relative to status at ad-
mission, the right lateral ventricle also had enlarged
somewhat, due to obstruction at foramen of Monro
(Fig. 1b). In light of this intransigence, surgical debulking
of tumor was elected first, through craniotomy and then via
transsphenoidal approach. The hardened elastic quality of
the tumor and its strong attachments to neighboring
structures prevented complete removal, but related
mass effect was significantly reduced and serum PRL
level declined (to 250 ng/ml) in steps at each procedural
stage. But the normalization of PRL level had not been
achieved with the administration of cabergoline increasedFig. 2 H&E staining of prolactinoma. Pleomorphic ovoid tumor cells in den
and prominent nucleoli seen in higher magnification (b); proliferation of sp
vessel walls as frequent finding (d)up to 0.5 mg/day. The residual tumor showed no evidence
of regrowth or distant metastasis 1 year after surgery.
Histopathologically, hematoxylin and eosin (H&E)-
stained sections of specimens from the first and second
surgical procedures similarly were composed of polygonal
and spindle cells with round, oval, or elongated nuclei and
eosinophilic cytoplasm (Fig. 2a–c). The cells formed irregu-
lar nests or short fascicles, accompanied by frequent hyaline
changes in vessel walls and vacuolation (Fig. 2d). Some
nuclear pleomorphism was prominent; on the other hand,
neither a high mitotic rate nor necrosis was evident (Fig. 2b,
c). Conspicuous fibrous change of tumor stroma was noted
focally as well (Fig. 3a). The chromophobic nature of
tumor cells was confirmed by Pearse’s Periodic Acid Schiff
(PAS) stain (Fig. 3b). Immunostains showed strong diffusese and disorderly proliferation (a); atypical multinucleated giant cells
indle cells with elongated nuclei and prominent nucleoli (c); hyalinized
Fig. 3 Immunohistochemistry of prolactinoma. Conspicuous fibrous change in tumor confirmed by Masson trichrome stain (a); Pearse’s PAS stain
verifying chromophobic tumor cells (b); strong reactivity of tumor cells for PRL, with paranuclear localization (c); tumor cells negative for S-100
protein (d)
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physin. No other hormones (GH, TSH, ACTH, LH, FSH)
were expressed by tumor cells, and the other markers, in-
cluding S-100 protein (Fig. 3d), glial fibrillary acidic protein
(GFAP), epithelial membrane antigen (EMA), cytokeratin
AE1/AE3 (CK AE1/AE3), vimentin, p53, and bcl-2, were
also negative by immunostaining. Ki-67 labeling index was
approximately 2 %.
A final diagnosis of PRL-producing pituitary adenoma
was reached after considering the immunohistochemical
profile, suprasellar location, and prolactin production of
the tumor, as well as the absence of metastatic foci and
invasion into surrounding tissue.
Discussion
The histopathologic traits of this tumor were highly un-
usual. Uniform, rounded, or polygonal cells with round-
to-oval nuclei are typically seen in pituitary adenomas.
In ordinary pituitary adenomas, cells are arranged in a
perisinusoidal fashion, and mitotic figures or necrotic
cells are rare. However, tumor morphology is known to
change following dopamine agonist (DA) treatment.
Moritetsu et al. reported necrotic changes in prolactino-
mas after long-term administration of bromocriptine,
also identifying acellular areas (from tumor involution)
where hyaline deposition and fibrosis were variably seen
and describing visible tumor atypism (hyperchromatic or
giant nuclei) [1]. After short-term exposure to DA,
apoptotic cells/bodies [2] and multinucleated giant cells
may be present [3], but fibrous change is exceptional. In
those instances where use of DA has altered tumor
morphology, therapeutic efficacy is commonly signaledby tumor involution and/or decline in serum PRL level,
plus diminished PRL immunoreactivity (especially in the
small cells that populate prolactinomas) [4]. In the pa-
tient reported here, broad fascicular fibrosis of tumor was
focally conspicuous, and overt cellular atypia was observed,
even though a relatively short course (4 weeks) of medical
therapy was given preoperatively. Considering that the
serum PRL level on admission was lowered by nearly one
half through medication, the effects of DA may account for
some of these manifestations. However, PRL immunoreac-
tivity persisted postoperatively, without apoptotic changes
or necrosis, none of this in keeping with response to DA.
The stromal fibrosis may possibly reflect the longer period
of growth and greater size of this lesion. There have been
sporadic reports of pituitary adenomas that histologically
show cellular atypia and bizarre nuclei. Matsumoto et al.
have also documented a growth-hormone-producing giant
pituitary adenoma with marked cellular atypia, and Mori-
waki et al. have a recurrent pituitary adenoma harboring
huge, bizarre nuclei [5].
In instances where an intracranial mass and hyperpro-
lactinemia coexist, dysfunction of the hypophyseal stalk
due to the mass effect of various tumors (i.e., chordoma,
schwannoma, paraganglioma, or mixed germ cell tumor)
[6] and tumors arising near sella, other than prolactinoma,
must be considered. Differential diagnosis was required
since the histological findings in this case were different
from that of typical pituitary adenoma. In particular, the
proliferation of spindle cells was striking, implicating a host
of diagnostic possibilities (see Table 1). Spindle cell oncocy-
toma (SCO) contains fascicles of eosinophilic spindle cells
with granular cytoplasm, and its immunophenotype is
Table 1 Histology and immunostaining in differential diagnosis of tumors
Staining Case
presentation














































± ± − − − − −
Cytokeratin − ± − − − 5 % −
EMA − >50 % − − + + −
S-100 protein − − + + + 20 % +
Vimentin − − − ± + + +
GFAP − − + ± − − ±
Synaptophysin + + − + − − −
Chromogranin-
A
+ 90 % − 95 % − − −
EMA epithelial membrane antigen, GFAP glial fibrillary acidic protein
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for pituitary hormones, synaptophysin, chromogranin, and
cytokeratins) [7]. Pituicytoma consists of elongated, bipolar
spindle cells in interlacing fascicles or storiform array, with
variable immunopositivity for vimentin, S-100 protein, and
GFAP [7]. Paragangliomas regularly exhibit nested patterns
(Zellballen configuration) and are rimmed by sustentacular
cells. The latter generally are immunopositive for GFAP,
chromogranin-A, and neuron-specific enolase, and susten-
tacular cells are positive for S-100 protein [8].
This patient’s tumor cells were giant atypical nuclei, giv-
ing the impression of malignancy. Pituitary carcinomas do
not always show nuclear atypia, pleomorphism, necrosis,Table 2 Antibodies used for immunohistochemical study





Cytokeratin Leica BOND Proteinas
EMA DAKO Tris/EDTA
S-100 protein Nichirei None
Vimentin Leica BOND Tris/EDTA
GFAP Leica BOND Tris/EDTA
Synaptophysin Leica BOND Tris/EDTA
Chromogranin-A DAKO Tris/EDTA
bcl-2 DAKO Tris/EDTA
TP53 Leica BOND Tris/EDTA
Ki-67 DAKO Tris/EDTAand hemorrhage as conventional indicators of malignancy,
but mitotic count or Ki-67 labeling index is apt to be in-
creased, with a clear tendency for cerebrospinal or sys-
temic metastases. In this case, the tumor cells were
proven chromophobic by Pearse’s PAS stain, showing
immunopositivity for PRL, chromogranin-A, and synapto-
physin but no immunoreactivity to S-100 protein, vimen-
tin, and GFAP. Mitotic figures were scarce in tissue
samples, and the Ki-67 labeling index was approximately
2 %. This immunohistochemical profile is quite compat-
ible with pituitary adenoma. The details of antibodies
used for immunohistochemical study are summarized in





e K Mouse monoclonal 1:100
pH 8 Mouse monoclonal 1:100
Rabbit polyclonal Predilute
pH 8 Mouse monoclonal 1:200
pH 8 Mouse monoclonal 1:300
pH 8 Mouse monoclonal 1:100
pH 8 Mouse monoclonal 1:400
pH 8 Mouse monoclonal 1:1000
pH 8 Mouse monoclonal 1:40
pH 8 Mouse monoclonal 1:400
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Herein, we describe a patient who underwent treatment
for a sizeable and visibly atypical prolactinoma. Similar
to PRL-producing adenomas, sellar tumors also may ex-
hibit hyperprolactinemia. Furthermore, DA administration
can cause secondary changes in the histological appear-
ance of the tumor. Thus, histopathological diagnosis can
be extremely challenging in cases of PRL-producing aden-
omas characterized by remarkable spindle-shaped cells
with nuclear pleomorphism, as described in the present
study.
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